Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
It belongs to a novel class of agents known as triple receptor agonists , distinguishing it from earlier-generation treatments such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist)
It is administered once weekly via subcutaneous injection, starting at 0.25 mg for the first four weeks and gradually increasing to 0.5 mg, 1.0 mg, and up to 2.4 mg as needed, based on the patients response and treatment goals
Healthcare (Basel) 11 , 93 (2022)
Cartilage and joint research applications demonstrate FOXO4-DRI's utility in tissue engineering and regenerative medicine studies
Injecting into areas of lipodystrophy, scar tissue, or inflamed skin may result in erratic absorption and unpredictable drug levels
US$ 27.43
US$ 20.65
US$ 26.54
US$ 21.35
US$ 28.92
US$ 28.11
